Effect of selective serotonin reuptake inhibitors on cardiovascular morbidity and mortality

J Cardiovasc Pharmacol Ther. 2008 Mar;13(1):32-40. doi: 10.1177/1074248407308467.

Abstract

Depression in patients with coronary artery disease is associated with increased cardiovascular morbidity and mortality. It is not clear, however, if treatment with selective serotonin reuptake inhibitors (SSRIs) decreases the rate of future cardiovascular events. This paper reviews the available literature regarding the effect of SSRI use on cardiovascular outcomes. Thirteen studies addressing this issue were identified. Of these, 5 concluded that SSRI use is associated with decreased cardiovascular morbidity or mortality, 2 concluded that SSRI use was associated with worsened prognosis, and 6 studies found no statistically significant association. Almost all of the published literature examining the effect of SSRIs on cardiovascular outcomes is based on observational studies, thereby precluding definitive conclusions. Randomized controlled studies are clearly needed to definitively address this issue.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antidepressive Agents / therapeutic use
  • Cardiovascular Diseases / complications*
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / mortality
  • Clinical Trials as Topic
  • Coronary Artery Disease / complications
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / etiology
  • Humans
  • Prognosis
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*

Substances

  • Antidepressive Agents
  • Serotonin Uptake Inhibitors